Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News LianBio LIANY

Healthcare Biotechnology
LianBio is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing medicines for patients with unmet medical needs, with a focus on in-licensing assets for Greater China and other Asian markets. It has a pipeline of eight therapeutic candidates across cardiovascular, oncology, ophthalmology, and inflammatory disease indications. Its product... see more

Recent & Breaking News (PINL:LIANY)

LianBio Announces Voluntarily Delisting from Nasdaq

GlobeNewswire February 28, 2024

LianBio Announces Completion of Strategic Review

GlobeNewswire February 13, 2024

LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets

GlobeNewswire December 26, 2023

LianBio Announces Departure of Chief Financial Officer

GlobeNewswire December 20, 2023

LianBio Announces Departure of Chief Executive Officer

GlobeNewswire December 19, 2023

LianBio's Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra Biosciences

GlobeNewswire December 6, 2023

LianBio Confirms Receipt of Unsolicited Proposal from Concentra Biosciences

GlobeNewswire December 1, 2023

LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 13, 2023

LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

GlobeNewswire October 30, 2023

LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023

GlobeNewswire October 25, 2023

LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets

GlobeNewswire October 24, 2023

LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten Presented at the European Society of Cardiology Congress and Simultaneous Publication in JAMA Cardiology

GlobeNewswire August 28, 2023

LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire August 14, 2023

LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations

GlobeNewswire August 3, 2023

LianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVY(TM) (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex Blepharitis

GlobeNewswire July 26, 2023

LianBio Partner NANOBIOTIX Enters into License Agreement with Janssen for Radioenhancer NBTXR3, with LianBio Retaining Development and Commercialization Rights in Greater China, South Korea, Singapore and Thailand

GlobeNewswire July 18, 2023

LianBio Announces Phase 3 EXPLORER-CN Data Accepted for Late-Breaking Presentation at the European Society of Cardiology Congress 2023

GlobeNewswire July 17, 2023

LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations

GlobeNewswire July 12, 2023

LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in Singapore

GlobeNewswire June 26, 2023

LianBio Completes Enrollment in Pivotal Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

GlobeNewswire June 8, 2023